HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis
NASDAQ:HBIO - Nasdaq - US4169061052 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to HBIO. HBIO was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of HBIO have multiple concerns. HBIO has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year HBIO was profitable.
HBIO had a positive operating cash flow in the past year.
HBIO had negative earnings in each of the past 5 years.
HBIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
HBIO has a worse Return On Assets (-72.74%) than 87.27% of its industry peers.
With a Return On Equity value of -391.31%, HBIO is not doing good in the industry: 87.27% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.74% | ||
| ROE | -391.31% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HBIO has a Gross Margin of 57.09%. This is in the better half of the industry: HBIO outperforms 70.91% of its industry peers.
In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
HBIO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HBIO has been increased compared to 5 years ago.
Compared to 1 year ago, HBIO has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.59, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.59, HBIO is not doing good in the industry: 83.64% of the companies in the same industry are doing better.
HBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.59 |
ROIC/WACCN/A
WACC10.21%
2.3 Liquidity
A Current Ratio of 0.81 indicates that HBIO may have some problems paying its short term obligations.
HBIO has a worse Current ratio (0.81) than 90.91% of its industry peers.
A Quick Ratio of 0.40 indicates that HBIO may have some problems paying its short term obligations.
With a Quick ratio value of 0.40, HBIO is not doing good in the industry: 96.36% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.4 |
3. Growth
3.1 Past
The earnings per share for HBIO have decreased strongly by -72.73% in the last year.
Measured over the past years, HBIO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.73% on average per year.
The Revenue for HBIO has decreased by -14.41% in the past year. This is quite bad
The Revenue has been decreasing by -4.12% on average over the past years.
EPS 1Y (TTM)-72.73%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%-150%
Revenue 1Y (TTM)-14.41%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.17%
3.2 Future
The Earnings Per Share is expected to grow by 20.21% on average over the next years. This is a very strong growth
HBIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.01% yearly.
EPS Next Y-23.5%
EPS Next 2Y20.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-7.04%
Revenue Next 2Y1.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 15.57 indicates a correct valuation of HBIO.
Compared to the rest of the industry, the Price/Earnings ratio of HBIO indicates a somewhat cheap valuation: HBIO is cheaper than 74.55% of the companies listed in the same industry.
HBIO's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.25.
With a Price/Forward Earnings ratio of 5.39, the valuation of HBIO can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 98.18% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.15, HBIO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.57 | ||
| Fwd PE | 5.39 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HBIO is valued a bit cheaper than the industry average as 61.82% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 26.48 |
4.3 Compensation for Growth
HBIO's earnings are expected to grow with 20.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.21%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.467
-0.2 (-30.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners82.92%
Inst Owner Change-17.26%
Ins Owners7.23%
Ins Owner Change-1.6%
Market Cap20.65M
Analysts80
Price Target4.59 (882.87%)
Short Float %3.15%
Short Ratio2.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.57%
Min EPS beat(2)17.65%
Max EPS beat(2)75.49%
EPS beat(4)2
Avg EPS beat(4)-45.1%
Min EPS beat(4)-173.52%
Max EPS beat(4)75.49%
EPS beat(8)2
Avg EPS beat(8)-41.43%
EPS beat(12)4
Avg EPS beat(12)-35.76%
EPS beat(16)4
Avg EPS beat(16)-30.39%
Revenue beat(2)1
Avg Revenue beat(2)5.44%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)11.18%
Revenue beat(4)1
Avg Revenue beat(4)-4.56%
Min Revenue beat(4)-14.86%
Max Revenue beat(4)11.18%
Revenue beat(8)1
Avg Revenue beat(8)-5.8%
Revenue beat(12)2
Avg Revenue beat(12)-5.61%
Revenue beat(16)4
Avg Revenue beat(16)-3.95%
PT rev (1m)20%
PT rev (3m)-28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-114.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-64%
Revenue NQ rev (1m)-4.67%
Revenue NQ rev (3m)-15.53%
Revenue NY rev (1m)-1.58%
Revenue NY rev (3m)-10.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.57 | ||
| Fwd PE | 5.39 | ||
| P/S | 0.23 | ||
| P/FCF | N/A | ||
| P/OCF | 6.83 | ||
| P/B | 1.39 | ||
| P/tB | N/A | ||
| EV/EBITDA | 26.48 |
EPS(TTM)0.03
EY6.42%
EPS(NY)0.09
Fwd EY18.57%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.07
OCFY14.64%
SpS2.07
BVpS0.34
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.74% | ||
| ROE | -391.31% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.09% | ||
| FCFM | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 45.88% | ||
| Cap/Sales | 3.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 133.35% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.4 | ||
| Altman-Z | -2.59 |
F-Score4
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.73%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%-150%
EPS Next Y-23.5%
EPS Next 2Y20.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.41%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.17%
Revenue Next Year-7.04%
Revenue Next 2Y1.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-123.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4733.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-105.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.93%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%